Patients affected by non fatal new myocardial infarction (STEMI and N-STEMI) MedDRA version: 12.0 Level: LLT Classification code 10000891 Term: Acute myocardial infarction
Conditions
Interventions
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Ascorbic acid (vit C)
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 500-
Pharmaceutical form of the placeb
Sponsors
UNIVERSITA` DEGLI STUDI DI PARMA
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: -Patients of either gender, age> 25 years and =65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: -patients suffered from cardiogenic shock, hypotension ( systolic blood pressure less than 100 mmHg for at least 30 minutes, pulmonary oedema, mayor arrhythmias, -without major systemic illnesses -renal insufficiency (GFR < 30 ml/min) and -pregnancy or oral contraceptives -Alcoholism
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: -Examine the time-course of endothelial function using a new noninvasive computerized technique (flow mediated dilation, FMD) in patients with AMI (acute phase and 20 40 days after). -Asses the benefit of vitamin C oral administration (500 mg/24h) on endothelial dysfunction in patients with non fatal new myocardial infarction .;Secondary Objective: -Evaluate the effects of vitamin C oral administration (500 mg/24h) on serum concentrations of the main systemic and vascular inflammation markers.;Primary end point(s): Endothelial function improvement | — |
Countries
Italy
Outcome results
None listed